[1]
Hartnett, M.E.; Penn, J.S. Mechanisms and management of retinopathy of prematurity. N. Engl. J. Med., 2012, 367(26), 2515-2526.
[2]
Liegl, R. Hellström. A.; Smith, L.E. Retinopathy of prematurity: The need for prevention. Eye Brain, 2016, 8, 91-102.
[3]
Kong, L.; Bhatt, A.R.; Demny, A.B.; Coats, D.K.; Li, A.; Rahman, E.Z.; Smith, O.E.; Steinkuller, P.G. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci., 2015, 56(2), 956-961.
[4]
Hellström, A.; Engström, E.; Hård, A.L.; Albertsson-Wikland, K.; Carlsson, B.; Niklasson, A.; Löfqvist, C.; Svensson, E.; Holm, S.; Ewald, U.; Holmström, G.; Smith, L.E. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics, 2003, 112(5), 1016-1020.
[5]
Hellstrom, A.; Perruzzi, C.; Ju, M.; Engstrom, E.; Hard, A.L.; Liu, J.L.; Albertsson-Wikland, K.; Carlsson, B.; Niklasson, A.; Sjodell, L.; LeRoith, D.; Senger, D.R.; Smith, L.E. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: Direct correlation with clinical retinopathy of prematurity. Proc. Natl. Acad. Sci. USA, 2001, 98(10), 5804-5808.
[6]
Matano, F.; Yoshida, D.; Ishii, Y.; Tahara, S.; Teramoto, A.; Morita, A. Endocan, a new invasion and angiogenesis marker of pituitary adenomas. J. Neurooncol., 2014, 117(3), 485-491.
[7]
Abu El-Asrar, A.M.; Nawaz, M.I.; De Hertogh, G.; Al-Kharashi, A.S.; Van den Eynde, K.; Mohammad, G.; Geboes, K. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Curr. Eye Res., 2015, 40(3), 321-331.
[8]
Theodoropoulou, S.; Copland, D.A.; Liu, J.; Wu, J.; Gardner, P.J.; Ozaki, E.; Doyle, S.L.; Campbell, M.; Dick, A.D. Interleukin-33 regulates tissue remodelling and inhibits angiogenesis in the eye. J. Pathol., 2017, 241, 45-56.
[9]
Kliegman, R.M.; Walsh, M.C. Neonatal necrotizing enterocolitis: pathogenesis, classification, and spectrum of illness. Curr. Probl. Pediatr., 1987, 17(4), 213-288.
[10]
Walsh, M.C.; Wilson-Costello, D.; Zadell, A.; Newman, N.; Fanaroff, A. Safety, reliability, and validity of a physiologic definition of bronchopulmonary dysplasia. J. Perinatol., 2003, 23(6), 451-456.
[11]
Papile, L.A.; Burstein, J.; Burstein, R.; Koffler, H. Incidence and evolution of subependymal and intraventricular hemorrhage: A study of infants with birth weights less than 1,500 gm. J. Pediatr., 1978, 92(4), 529-534.
[12]
International Committee for the Classification of Retinopathy of Prematurity.The international classification of retinopathy of prematurity revisited. Arch. Ophthalmol., 2005, 123(7), 991-999.
[13]
Ezz-Eldin, Z.M.; Hamid, T.A.; Youssef, M.R. Nabil, Hel-D. Clinical risk index for babies (CRIB II) scoring system in prediction of mortality in premature babies. J. Clin. Diagn. Res., 2015, 9(6), SC08-SC11.
[14]
Shah, P.K.; Prabhu, V.; Karandikar, S.S.; Ranjan, R.; Narendran, V.; Kalpana, N. Retinopathy of prematurity: Past, present and future. World J. Clin. Pediatr., 2016, 5(1), 35-46.
[15]
Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch. Ophthalmol., 1988, 106(4), 471-479.
[16]
Early Treatment For Retinopathy Of Prematurity Cooperative Group.Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial. Arch. Ophthalmol., 2003, 121(12), 1684-1694.
[17]
Heidary, G.; Vanderveen, D.; Smith, L.E. Retinopathy of prematurity: Current concepts in molecular pathogenesis. Semin. Ophthalmol., 2009, 24(2), 77-81.
[18]
Hellström, A.; Ley, D.; Hansen-Pupp, I.; Hallberg, B.; Ramenghi, L.A.; Lofqvist, C.; Smith, L.E.; Hard, A.L. Role of insulinlike growth factor 1 in fetal development and in the early postnatal life of premature infants. Am. J. Perinatol., 2016, 33(11), 1067-1071.
[19]
Hellström, A.; Ley, D.; Hansen-Pupp, I.; Hallberg, B.; Ramenghi, L.A.; Löfqvist, C.; Smith, L.E.; Hård, A.L. IGF-I in the clinics: Use in retinopathy of prematurity. Growth Horm. IGF Res., 2016, •••, 75-80.
[20]
Pérez-Muñuzuri, A.; Fernández-Lorenzo, J.R.; Couce-Pico, M.L.; Blanco-Teijeiro, M.J.; Fraga-Bermúdez, J.M. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr., 2010, 99(4), 519-525.
[21]
Kandasamy, Y.; Hartley, L.; Rudd, D.; Smith, R. The association between systemic vascular endothelial growth factor and retinopathy of prematurity in premature infants: A systematic review. Br. J. Ophthalmol., 2017, 101(1), 21-24.
[22]
Rennel, E.; Mellberg, S.; Dimberg, A.; Petersson, L.; Botling, J.; Ameur, A.; Westholm, J.O.; Komorowski, J.; Lassalle, P.; Cross, M.J.; Gerwins, P. Endocan is a VEGF-A and PI3K regulated gene with increased expression in human renal cancer. Exp. Cell Res., 2007, 313(7), 1285-1294.
[23]
Chen, L.Y.; Liu, X.; Wang, S.L.; Qin, C.Y. Over-expression of the Endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumour invasion. J. Int. Med. Res., 2010, 38(2), 498-510.
[24]
Roudnicky, F.; Poyet, C.; Wild, P.; Krampitz, S.; Negrini, F.; Huggenberger, R.; Rogler, A.; Stöhr, R.; Hartmann, A.; Provenzano, M.; Otto, V.I.; Detmar, M. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res., 2013, 73(3), 1097-1106.
[25]
Su, T.; Zhong, Y.; Demetriades, A.M.; Shen, J.; Sui, A.; Yao, Y.; Gao, Y.; Zhu, Y.; Shen, X.; Xie, B. Endocan blockade suppresses experimental ocular neovascularization in mice. Invest. Ophthalmol. Vis. Sci., 2018, 59(2), 930-939.
[26]
Liu, X.C.; Liu, X.F.; Jian, C.X.; Li, C.J.; He, S.Z. IL-33 is induced by amyloid-β stimulation and regulates inflammatory cytokine production in retinal pigment epithelium cells. Inflammation, 2012, 35(2), 776-784.
[27]
Halil, H.; Tayman, C.; Buyuktiryaki, M.; Okur, N.; Cakir, U.; Serkant, U. Serum interleukin-33 as a biomarker in predicting neonatal sepsis in very low birth weight infants. Comb. Chem. High Throughput Screen., 2018, 21, 510-515.
[28]
Choi, Y.S.; Choi, H.J.; Min, J.K.; Pyun, B.J.; Maeng, Y.S.; Park, H.; Kim, J.; Kim, Y.M.; Kwon, Y.G. Interleukin-33 induces angiogenesis and vascular permeability through ST2/TRAF6-mediated endothelial nitric oxide production. Blood, 2009, 114(14), 3117-3126.
[29]
Milosavljevic, M.Z.; Jovanovic, I.P.; Pejnovic, N.N.; Mitrovic, S.L.; Arsenijevic, N.N. Simovic, Markovic, B.J.; Lukic, M.L. Deletion of IL-33R attenuates VEGF expression and enhances necrosis in mammary carcinoma. Oncotarget, 2016, 7(14), 18106-18115.
[30]
Yalin, Imamoglu,. E.; Gunay, M.; Gursoy, T.; Imamoglu, S.; Balci, Ekmekci.; Celik, G.; Karatekin, G.; Ovali, F. Effect of laser photocoagulation on plasma levels of VEGF-A, VEGFR-2, and Tie2 in infants with retinopathy of prematurity. J. AAPOS, 2014, 18(5), 466-470.
